Latest Healthcare Research Reports

Category: Pharmaceuticals

Comprehensive Analysis On Size, Share, And Drivers Of The Animal Feed Protein Market
The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Market Growth Overview

The animal feed protein market has shown significant growth in recent years. From $286.91 billion in 2023, it is projected to reach $301.67 billion in 2024, marking a compound annual growth rate (CAGR) of 5.1%. Key factors driving this growth include:
- Rising Demand for Animal Products: Increased consumption of meat, dairy, and eggs.
- Population Growth and Urbanization: More people living in cities, requiring more efficient food production.
- Livestock Farming Intensification: Improved farming techniques to meet growing demand.
- Nutritional Requirements for Livestock: Enhanced feed formulations for better livestock health.
- Globalization of the Livestock Industry: Expansion of livestock farming practices worldwide.
Future Market Projections

Looking ahead, the market is expected to grow even further, reaching $372.95 billion by 2028 with a CAGR of 5.4%. This growth can be attributed to several emerging factors:
- Growing Awareness of Sustainable Diets: Increased interest in eco-friendly and health-conscious food options.
- Shift Towards Plant-Based Proteins: Rising popularity of plant-derived protein sources.
- Regulatory Emphasis on Livestock Health: Stricter health and safety standards for animal products.
- Technological Innovations in Feed Formulation: Advancements in creating more efficient and nutritious feeds.
- Focus on Circular Economy: Emphasis on recycling and sustainable production practices.
View More On The Animal Feed Protein Market Report 2024 – https://www.thebusinessresearchcompany.com/report/animal-feed-protein-global-market-report

Major Trends in the Market

Several key trends are shaping the future of the animal feed protein market:
- Sustainable and Ethical Sourcing: Greater focus on sourcing ingredients responsibly.
- Biotechnological Innovations: Use of biotechnology to enhance protein production.
- Alternative Protein Ingredients: Exploration of new protein sources like insects and algae.
- Customized Protein Blends: Tailoring protein mixes to specific livestock needs.
- CRISPR Technology: Utilizing gene editing to improve protein quality and quantity.
Surge in Meat Products Demand

The increasing global demand for meat products is a significant driver of the animal feed protein market. Notable points include:
- Global Meat Production Growth: In 2021, global meat production grew by 5%, driven largely by a 34% increase in pig meat production in China.
- High Protein Consumption: Americans, on average, consume significantly more protein than required, indicating strong market demand for animal products.
Leading Companies in the Market

The animal feed protein market features several major players, including:
- Cargill Incorporated
- Archer Daniels Midland Company
- Tyson Foods Inc.
- CHS Inc.
- Nitta Gelatin Inc.
These companies are at the forefront of innovation and market expansion.

Product Innovation in Animal Feed Protein

Product innovation is a crucial trend in this market. For example:
- BASF SE’s Natupulse: Launched in December 2021, this enzyme product enhances feed digestibility and nutrient utilization, making animal feeding more cost-effective and sustainable.
Strategic Acquisitions

Acquisitions are strengthening the market positions of key players:
- United Petfood Producers NV: Acquired Gold Line Feeds Ltd. in October 2022 to expand its presence in the UK animal feed market.
Market Segmentation

The animal feed protein market is segmented by:
1. Product: Plant Protein, Animal Protein, Alternative Protein
2. Livestock: Poultry, Swine, Cattle, Aquaculture, Petfood, Equine
3. Form: Dry, Liquid
Regional Insights
- Asia-Pacific: The largest region in the animal feed protein market as of 2023, indicating a strong demand and significant growth opportunities in this region.
Conclusion

The animal feed protein market is poised for substantial growth, driven by rising meat demand, innovative product development, and strategic industry moves. Stakeholders should focus on sustainable practices, technological advancements, and regional market dynamics to capitalize on this expanding market.

Request A Sample Of The Global Animal Feed Protein Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=9391&type=smp
May 27, 2024
Top 5 Insights From The Precision Medicine Market Report 2024
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Precision Medicine Global Market Report 2024, the precision medicine market is expected to show promising growth in the forecast period.

Overview

The precision medicine market is experiencing substantial growth, driven by various factors including increased disease prevalence and advancements in research and technology. In this blog, we will explore the factors fueling this growth, key trends, and notable industry developments.

Market Growth Dynamics
- Current Market Size and Growth: The precision medicine market size has grown from $73.11 billion in 2023 to an expected $81.06 billion in 2024, with a compound annual growth rate (CAGR) of 10.9%.
- Future Projections: By 2028, the market is expected to reach $118.08 billion, growing at a CAGR of 9.9%.
Factors Contributing to Historic Growth
- Increased Disease Prevalence: Rising cases of cancer, respiratory diseases, and mental health disorders have driven the demand for precision medicine.
- Geriatric Population: An aging population requires more targeted and effective treatments.
- Funding and Expenditure: Increased funding and higher pharmaceutical R&D and healthcare expenditures have bolstered market growth.
View More On The Precision Medicine Market Report 2024 – https://www.thebusinessresearchcompany.com/report/precision-medicine-global-market-report

Forecasted Growth Drivers
- Emerging Economies: High growth potential in emerging markets.
- Novel Pathogens: Emergence of new pathogenic infestations necessitates advanced medical solutions.
- R&D Investment: Continued increase in research and development spending.
- Healthcare Expenditure: Rising overall healthcare expenditure supports the expansion of precision medicine.
Key Trends in Precision Medicine
- Artificial Intelligence Integration: Adoption of AI technologies to enhance diagnostic and treatment capabilities.
- Personalized Treatments: Focus on personalized treatment for immune-mediated diseases.
- Collaborations and Partnerships: Formation of strategic alliances to enhance product portfolios.
Impact of Rising Cancer Prevalence
- Cancer Statistics: One in five individuals is expected to develop cancer, making it a leading cause of death globally.
- Genetic Analysis: Precision medicine involves analyzing tumor DNA to identify mutations and tailor treatments accordingly.
- Example: In the US, new cancer cases rose from 1.89 million in 2021 to 1.92 million in 2022, underscoring the need for precision medicine.
Innovative Research Initiatives
- Harvard-Clalit Partnership: In August 2021, Harvard Medical School and Clalit Research Institute launched a joint precision medicine research initiative, thanks to a donation from the Berkowitz family.
- Objective: Focus on converting data insights into clinical interventions, setting up the first precision medicine clinic for tailored therapies.
Strategic Acquisitions
- Servier Laboratories and Agios Pharmaceuticals: In April 2021, Servier Laboratories acquired Agios Pharmaceuticals’ oncology portfolio to strengthen its presence in the precision oncology market.
- Benefits: This acquisition enhances Servier’s commercial presence and expands its pipeline in oncology precision medicine.
Market Segmentation
- By Technology: Includes Big Data Analytics, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, and other technologies.
- By Application: Covers Oncology, Respiratory Diseases, Central Nervous System Disorders, Immunology, Genetic Diseases, among others.
- By End-Use: Encompasses Pharmaceutical Companies, Diagnostic Companies, Healthcare and IT Firms, and others.
Regional Insights
- North America: The largest region in the precision medicine market as of 2023.
- Asia-Pacific: Projected to be the fastest-growing region during the forecast period.
Conclusion

The precision medicine market is poised for robust growth, driven by advancements in technology, increased disease prevalence, and strategic industry collaborations. As the market continues to evolve, it promises to revolutionize the approach to diagnosing and treating various diseases, making personalized medicine a cornerstone of future healthcare.

Request A Sample Of The Global Precision Medicine Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=5301&type=smp
May 24, 2024
Regenerative Medicine For Cartilage Market Report 2024: Market Size, Drivers, And Trends
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

Unveiling the Growth Trajectory
- Market size surged from $4.24 billion in 2023 to $4.48 billion in 2024.
- Expected to reach $5.64 billion by 2028 with a CAGR of 5.9%.
Understanding the Growth Drivers

Sustained Rise in Chronic Diseases
- Chronic diseases, such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes, drive demand.
- Chronic conditions necessitate long-term solutions like regenerative medicine for cartilage.
Technological Advancements and Healthcare Expenditure
- Advancements in regenerative medicine technology fuel market growth.
- Increased healthcare spending supports research and development in regenerative medicine.
View More On The Regenerative Medicine For Cartilage Market Report 2024 – https://www.thebusinessresearchcompany.com/report/regenerative-medicine-for-cartilage-global-market-report

Key Trends Shaping the Future

Advancements in Mesenchymal Stem Cell Technology
- Mesenchymal stem cell technology gains traction for cartilage repair.
- Offers promising results in tissue regeneration.
Innovative Gene Therapy Techniques
- Research and development focus on novel gene therapy approaches.
- Gene-based regenerative medicine holds potential for effective treatments.
Strategic Collaborations and Partnerships
- Industry players form alliances to accelerate research and development.
- Collaborations foster innovation and market growth.
Role of Injectable Hydrogel in Cartilage Repair
- Injectable hydrogels emerge as a regenerative medicine solution.
- Offers a minimally invasive approach for cartilage regeneration.
Global Research Initiatives and Funding
- Increased funding drives global research initiatives.
- Collaborative efforts propel advancements in regenerative medicine.
Prominent Players in the Market

Leading Companies
- Smith & Nephew PLC
- Integra LifeSciences
- Stryker Corporation
- Zimmer Biomet Holdings Inc.
- MiMedx Group, Inc.
Key Mergers and Acquisitions
- Cesca Therapeutics Inc. acquires remaining 20% equity share of ThermoGenesis Corp.
- Strengthens cellular manufacturing platform for regenerative medicine.
Segmentation of the Market

Product Segmentation
- Cell Based
- Gene Based
- Tissue Based
End-Use Segmentation
- Ambulatory Surgical Centers
- Hospitals And Clinics
- Others
Application Segmentation
- Musculoskeletal
- Oncology
- Dental
- Wound Care
- Others
Regional Dominance

Europe Leads the Way
- Europe emerged as the largest region in regenerative medicine for cartilage in 2023.
- Significant advancements and investments contribute to market leadership.
As the regenerative medicine for cartilage market continues to thrive, fueled by technological innovations, strategic partnerships, and rising healthcare needs, the landscape of cartilage repair is undergoing a transformative evolution. With promising growth projections and a focus on addressing chronic diseases, the journey towards effective regenerative solutions for cartilage repair is set to redefine the future of healthcare.

Request A Sample Of The Global Regenerative Medicine For Cartilage Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=3961&type=smp
May 24, 2024
5 Key Insights On The Photodynamic Therapy Market 2024
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Photodynamic Therapy Global Market Report 2024, the photodynamic therapy market is expected to show significant growth in the forecast period.

Overview of Market Growth

The photodynamic therapy (PDT) market has experienced significant growth recently, rising from $1.36 billion in 2023 to an expected $1.45 billion in 2024, with a compound annual growth rate (CAGR) of 7.0%.

Historical Growth Drivers
- Aging Population: Increasing elderly demographics needing medical care.
- Cancer Prevalence: Rise in various cancer types requiring effective treatments.
- Skin Diseases: Higher rates of skin conditions driving demand.
- Rising Pollution: Increased environmental factors affecting skin health.
- Healthcare Expenditure: More spending on advanced medical treatments.
- Healthcare Facilities: Growth in the number of medical institutions.
Future Market Projections

The PDT market is projected to continue its robust expansion, reaching $1.85 billion by 2028 with a CAGR of 6.2%.

Key Factors for Future Growth
- Healthcare Expenditure: Continued rise in spending on health services.
- Insurance Coverage: Increased coverage for PDT treatments.
- Emerging Economies: High growth potential in developing markets.
- Demographic Shifts: Growing teenage and older populations.
- Cancer and Chronic Diseases: Higher incidence rates necessitating advanced treatments.
- Infectious Diseases: Emerging diseases increasing the need for PDT.
View More On The Photodynamic Therapy Market Report 2024 – https://www.thebusinessresearchcompany.com/report/photodynamic-therapy-global-market-report

Major Trends in the Forecast Period
- Portable PDT Devices: Introduction of at-home treatment options.
- AI-Enabled PDT: Investments in artificial intelligence for improved patient outcomes.
- Cosmetic Procedures: Expansion of PDT applications in cosmetic treatments.
- Research and Development: Continued investment in advancing PDT technology.
- Photoimmunotherapy Devices: New devices enhancing immunotherapy.
- Photothermal Therapy: Expansion of PDT to include thermal applications.
Rising Prevalence of Skin Cancer

The increasing prevalence of skin cancer, particularly melanoma, is a significant driver for the PDT market.

Impact of Skin Cancer on PDT Growth
- Common Cancer: Skin cancer is the most diagnosed cancer type.
- Melanoma: Though only 1% of skin cancers, it causes a high number of deaths.
- Treatment Method: PDT uses light-sensitizing medication and intense light to destroy cancer cells.
- Statistics: According to the American Cancer Society, about 106,110 new melanomas were diagnosed in the USA in 2021.
Leading Companies in the PDT Market
- Galderma S.A.
- Bausch Health
- Lumenis Ltd.
- Sun Pharmaceutical Industries Ltd.
- Biofrontera
- Modlight Inc.
- PhotoMedex Inc.
- Soligenix Inc.
- MediGlobus
- Steba Biotech
- Ambicare Health
- Nuovo Therapy
- Pharmstandard
- Rusatom Healthcare
- Roche Latvija SIA
Growing Investments in AI-Powered PDT

Artificial intelligence is playing a transformative role in enhancing PDT for cancer diagnosis and treatment.

AI-Driven Advancements
- Enhanced Diagnostics: AI models improve cancer detection and treatment outcomes.
- Funding: Significant investments in AI to advance PDT technology.
- Example: Lumeda Inc. raised $5.3 million in Series A financing in 2021 to develop AI-driven PDT systems.
Strategic Acquisitions and Expansions

Fluoguide’s Acquisition for Photothermal Therapy
- Exclusive Rights: In March 2021, Fluoguide acquired rights to FG001 for photothermal therapy.
- Focus: Enhancing surgical outcomes in oncology.
Market Segmentation

By Product
- Drugs
- Devices
By Application
- Actinic Keratosis (AK)
- Cancer
- Acne
- Psoriasis
- Other Applications
By End-User
- Cosmetics and Dermatology Clinics
- Hospitals
- Cancer Treatment Centers
- Other End-Users
Regional Insights
- North America: The largest region in the PDT market in 2023, with continued growth expected due to advanced healthcare infrastructure and high adoption rates.
Conclusion

The photodynamic therapy market is poised for substantial growth, driven by rising cancer rates, technological advancements, and increasing healthcare investments. With ongoing innovation and strategic expansions, the PDT market will continue to evolve, offering improved treatments and expanding its applications across various medical and cosmetic fields.

Request A Sample Of The Global Photodynamic Therapy Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=5246&type=smp
May 24, 2024
Growth Trajectory Of The Gynecology Drugs Market 2024-2033
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

Robust Market Growth
- Recent Expansion: The gynecology drugs market has seen significant growth, increasing from $41.56 billion in 2023 to $43.78 billion in 2024, at a CAGR of 5.4%.
- Driving Factors:
  - Introduction of drugs with novel mechanisms.
  - Increased awareness and education on menopause.
  - Rise in long-acting reversible contraceptives.
  - Lifestyle changes and increased healthcare awareness.
  - Government initiatives and increased pharmaceutical R&D expenditure.
Future Growth Prospects
- Continued Growth Forecast: The market is expected to reach $54.1 billion by 2028, maintaining a CAGR of 5.4%.
- Key Drivers:
  - Growing awareness and use of contraceptives and hormone replacement therapy (HRT).
  - Rising incidence of age-related gynecological cancers.
  - Increased prevalence of ovarian cancer and other gynecological diseases.
  - Higher healthcare expenditure and investment in endometriosis research.
View More On The Gynecology Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/gynecology-drugs-global-market-report
- Emerging Trends:
  - Development of new treatment options for oncology and endometriosis.
  - Focus on new menopausal hormone therapies.
  - Strategic investments in research to develop innovative drugs.
  - Increasing awareness about contraceptive benefits and launching new products.
  - Development of antibody-drug conjugates (ADCs) targeted therapies for ovarian cancer.
  - Strategic collaborations to expand product portfolios and market presence.
  - Focus on combination therapies to overcome drug resistance and improve treatment outcomes.
Ovarian Cancer Surge Propels Market Growth
- Rising Ovarian Cancer Cases: The increasing incidence of ovarian cancer is driving the growth of the gynecological drugs market.
  - Significance: Gynecological drugs are crucial for managing ovarian cancer, improving survival rates, and enhancing patient quality of life.
  - Statistics: According to Globocan, the global incidence of ovarian cancer is expected to reach 434,184 cases by 2040, boosting the demand for gynecological drugs.
Innovation and Competition in the Market
Launch of Innovative Treatments
- New Drug Developments: Companies are focusing on launching advanced treatments to stay competitive.
  - Example: In September 2021, Myovant Sciences announced that the FDA accepted a supplemental New Drug Application (sNDA) for MYFEMBREE, targeting moderate to severe pain associated with endometriosis. This showcases the ongoing efforts to develop better treatments for gynecological conditions.
Strategic Acquisitions
- Carlyle and PAI Partners’ Acquisition of Theramex: In March 2022, Carlyle and PAI Partners acquired Theramex for $1.4 billion to expand their investment in women’s health products.
  - Objective: The acquisition aims to enhance Theramex’s portfolio through growth initiatives in fertility, contraception, menopause, and osteoporosis treatments.
Market Segmentation
- By Therapeutics:
  - Hormonal Therapy
  - Non-Hormonal Therapy
- By Indication:
  - Gynecology Cancers
  - Menopausal Disorder
  - Polycystic Ovary Syndrome
  - Contraception
  - Other Indications
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Regional Insights
- North America’s Dominance: North America was the largest region in the gynecology drugs market in 2023, driven by advanced healthcare infrastructure and high awareness levels.
- Asia-Pacific’s Rapid Growth: The Asia-Pacific region is expected to be the fastest-growing market during the forecast period, fueled by increasing healthcare investments and rising awareness of women’s health issues.
Conclusion
The gynecology drugs market is experiencing robust growth driven by innovative treatments, strategic acquisitions, and increased awareness of women’s health issues. With the market projected to continue its upward trajectory, there are significant opportunities for stakeholders to develop new drugs, expand their portfolios, and improve patient outcomes. As major players invest in research and strategic collaborations, the future of gynecology drugs looks promising, with substantial potential for advancing women’s health globally.

Request A Sample Of The Global Gynecology Drugs Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=4098&type=smp
May 23, 2024
Understand How The Pharmacovigilance Market Is Poised To Grow Through 2024-2033
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Pharmacovigilance Global Market Report 2024, the pharmacovigilance market is expected to show significant growth in the forecast period.

Market Overview:
- Rapid growth from $7.63 billion in 2023 to $8.67 billion in 2024.
- Compound annual growth rate (CAGR) of 13.6%.
Historic Growth Drivers:
- Increasing incidence of adverse drug reactions (ADRs).
- Growing research and development (R&D) activities.
- Accelerated drug development rates.
- Focus on personalized medicine.
- Rising prevalence of chronic diseases.
Future Projections:
- Expected to reach $14.11 billion by 2028.
- CAGR of 12.9%.
- Driven by rising healthcare expenditure.
- Increased government support.
- Aging population driving demand.
View More On The Pharmacovigilance Market Report 2024 – https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Emerging Trends:
- Increasing investments in pharmacovigilance.
- Use of artificial intelligence (AI).
- Adoption of innovative platforms.
- Cloud-based system advancements.
- Strategic mergers and acquisitions.
Research and Development Drive Growth:
- Investment in R&D:
  - Pharmaceutical companies developing innovative drugs.
  - Enhanced safety profiles through rigorous testing.
- Technological Advancements:
  - Improved adverse event monitoring.
  - Better data analysis and signal detection.
- Case Study:
  - IQVIA study in February 2022
shows venture capital deal activity and investment flows have surged in the life sciences sector. Over 2,000 agreements and $47 billion in deal value were projected in 2021.
- Top 15 pharmaceutical companies invested a record $133 billion in R&D in 2021, a 44% increase from previous years.
Embracing Artificial Intelligence for Enhanced Efficiency:
- AI Integration:
  - AI improves efficiency and accuracy in pharmacovigilance.
  - Streamlines processes, enhances data management, and accelerates drug discovery.
- Industry Collaboration:
  - In November 2021, Deloitte and Sanofi collaborated on ConvergeHEALTH Safety, an AI-driven adverse events case intake platform.
  - Initial deployment increased case quality and processing efficiency, allowing Sanofi to focus on optimizing benefit-risk profiles.
Strategic Acquisitions:
- AmerisourceBergen and Pharma Lex:
  - In January 2023, AmerisourceBergen acquired Pharma Lex to enhance its service offerings.
  - The acquisition provided comprehensive pharmacovigilance systems and benefit-risk management services.
  - Pharma Lex’s team in Germany contributed to end-to-end solutions in pharmacovigilance.
Market Segmentation:
1. By Type:
  - Spontaneous Reporting
  - Intensified ADR Reporting
  - Targeted Spontaneous Reporting
  - Cohort Event Monitoring
  - EHR Mining
2. By Service Provider:
  - In-House
  - Contract Outsourcing
3. By Process Flow:
  - Case Data Management
  - Signal Detection
  - Risk Management System
4. By Clinical Trial Phases:
  - Preclinical
  - Phase I
  - Phase II
  - Phase III
  - Phase IV
5. By End User:
  - Hospitals
  - Pharmaceutical Companies
  - Other End Users
Regional Insights:
- North America was the largest region in the pharmacovigilance market in 2023.
- Asia-Pacific is expected to be the fastest-growing region during the forecast period.
The pharmacovigilance market is experiencing robust growth driven by the increasing incidence of adverse drug reactions, expanding R&D activities, and the rising prevalence of chronic diseases. With a projected market size of $14.11 billion by 2028, the industry is set for significant advancements through the integration of AI, innovative platforms, and strategic acquisitions. As the market evolves, the focus on enhancing efficiency, improving safety profiles, and supporting personalized medicine will continue to drive growth and innovation in pharmacovigilance.

Request A Sample Of The Global Pharmacovigilance Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=5928&type=smp
May 23, 2024
Global Pharmaceutical Suppositories Market Key Insights 2024-2033
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Pharmaceutical Suppositories Global Market Report 2024, the pharmaceutical suppositories market is expected to show promising growth in the forecast period.

The pharmaceutical suppositories market has experienced substantial growth in recent years, driven by various factors such as increased healthcare expenditure and rising disease prevalence. In this blog, we will delve into the key drivers of market growth, future trends, and notable industry developments.

Market Growth Overview
- Recent Growth:
  - The market grew from $1.6 billion in 2023 to $1.7 billion in 2024, at a CAGR of 6.3%.
  - Growth drivers include increased healthcare expenditure, new regulatory approvals, government initiatives, a rise in constipation prevalence, and increasing disease incidence.
- Future Projections:
  - The market is expected to reach $2.19 billion by 2028, with a CAGR of 6.5%.
  - Future growth will be driven by an increase in the prevalence of kidney damage or failure, and hemorrhoids, alongside technological advancements and strategic partnerships.
View More On The Pharmaceutical Suppositories Market Report 2024 – https://www.thebusinessresearchcompany.com/report/pharmaceutical-suppositories-global-market-report

Catalyst for Pharmaceutical Suppositories Market Growth
- Increasing Disease Prevalence:
  - The rising prevalence of diseases is a significant driver for the market. Factors such as geography, climate, and disease-transmitting insects contribute to the higher incidence of various ailments.
  - Suppositories provide an effective drug delivery method, especially beneficial for patients with specific diseases.
- Case in Point:
  - According to the Australian Institute of Health and Welfare, over 4,700 hospitalizations were reported with COVID-19 in 2020–2021. This highlights the increasing need for diverse treatment methods, including suppositories.
Major Players in the Pharmaceutical Suppositories Market
- Key Companies:
  - Major companies in the market include Bayer AG, Pfizer Inc., Novartis International AG, Sanofi S.A., and Intas Pharmaceuticals Ltd.
  - Other notable players are Unither Pharmaceuticals, Cosette Pharmaceuticals, Inc., Aenova Holding GmbH, Delpharm, and Bliss GVS Pharma Ltd.
Transforming the Pharmaceutical Suppositories Market
- Technological Advancements:
  - Companies are leveraging advanced technologies to maintain their market positions.
  - Example: In March 2021, CB21 Pharma launched CANNEFF VAG SUP vaginal suppositories and CANNEFF SUP rectal suppositories for treating various mucous membrane and anorectal canal disorders.
- Product Innovations:
  - Innovations such as new formulations and improved delivery mechanisms are key trends.
  - Focus on patient convenience and adherence is driving product development.
Strategic Acquisitions
- Merck & Co. Acquisition:
  - In April 2023, Merck & Co. acquired Prometheus Biosciences for $10.8 billion. This acquisition is aimed at advancing treatments for ulcerative colitis and Crohn’s disease using monoclonal antibody therapy delivered through suppositories.
Market Segmentation
- By Type:
  - Segments include Rectal Suppositories, Vaginal Suppositories, Urethral Suppositories, and other types.
- By Base:
  - The market is divided into Fatty Base, Water Miscible Bases, and Emulsifying Bases.
- By End-User:
  - End-users include Hospitals and Clinics, Nursing Homes, Home Care, and other settings.
Regional Insights
- Current Leaders:
  - North America was the largest region in the pharmaceutical suppositories market in 2023, driven by high healthcare expenditure and advanced healthcare infrastructure.
- Fastest Growing:
  - Asia-Pacific is expected to be the fastest-growing region during the forecast period, attributed to increasing healthcare awareness and economic growth.
Conclusion

The pharmaceutical suppositories market is poised for significant growth, driven by increased disease prevalence, technological advancements, and strategic industry acquisitions. As healthcare needs continue to evolve, suppositories will remain a crucial drug delivery method, offering effective treatment options for a variety of conditions.

Request A Sample Of The Global Pharmaceutical Suppositories Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=8804&type=smp
May 23, 2024
Parenteral Nutrition Market Growth Analysis Till 2033 By The Business Research Company
The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

The parenteral nutrition market has been growing robustly and is poised for significant expansion in the coming years. This blog delves into the factors driving this growth, the key players, and the major trends shaping the market.

Recent Surge and Future Projections
- Current Market Size: The parenteral nutrition market grew from $6.48 billion in 2023 to $6.85 billion in 2024, with a compound annual growth rate (CAGR) of 5.8%.
- Future Growth: Expected to reach $8.67 billion by 2028, driven by a CAGR of 6.1%.
Factors Driving Growth

Rising Prevalence of Malnutrition Globally
- Global Malnutrition: Increasing malnutrition rates are significantly boosting the demand for parenteral nutrition.
  - Statistics: According to the World Health Organization, in 2021, 1.9 billion adults were overweight or obese, while 462 million were underweight.
  - Child Mortality: Around 45% of deaths among children under 5 years are linked to undernutrition.
Read More On The Parenteral Nutrition Market Report 2024 – https://www.thebusinessresearchcompany.com/report/parenteral-nutrition-global-market-report

Increasing Elderly Population and Urbanization
- Aging Population: The growing elderly population requires more nutritional support.
- Urbanization: Rapid urbanization and rising disposable income contribute to market growth.
Mergers and Acquisitions
- Market Consolidation: Increase in mergers and acquisitions among major companies to expand market presence.
Major Trends in the Market

Product Innovations
- New Products: Introduction of innovative products such as four-oil lipid injectable emulsions.
  - Example: In March 2022, Fresenius Kabi received US FDA approval for SMOFlipid lipid injectable emulsion for pediatric parenteral nutrition.
Use of Advanced Technologies
- Artificial Intelligence: Growing use of AI in the development and management of nutrition solutions.
- Focal Radio Frequency Technology: Innovations in noninvasive technologies to enhance patient outcomes.
Strategic Collaborations and Partnerships
- Partnerships: Companies forming strategic alliances to enhance research and development capabilities.
  - Example: Wellspring Capital Management’s acquisition of Pentec Health Inc. to strengthen its position in the specialty infusion sector.
Key Players in the Market
- Leading Companies:
  - Baxter International Inc.
  - Fresenius SE & Co. KGaA
  - Otsuka Pharmaceutical Factory Inc.
  - Braun Melsungen AG
  - Sichuan Kelun Pharmaceutical Co. Ltd.
  - American Regent Inc.
  - JW Pharmaceutical
  - Grifols S.A.
  - Amanta Healthcare
  - ICU Medical Inc.
  - Sanofi
  - Biogen Inc.
  - Pfizer Inc.
  - Actavis Inc.
Market Segmentation

By Composition
- Amino Acids
- Fats
- Carbohydrates
- Trace Elements
- Vitamins
- Minerals
- Other Compositions
By Consumer Type
- Children and New-born
- Adults
By End-User
- Hospitals
- Clinics
- Homecare
- Other End Users
Regional Insights
- Largest Market: North America was the largest region in the parenteral nutrition market in 2023.
- Fastest Growing Region: Asia-Pacific is expected to be the fastest-growing region during the forecast period.
Conclusion

The parenteral nutrition market is experiencing significant growth, driven by a combination of factors such as rising malnutrition, an aging population, and rapid urbanization. Innovations in product development and strategic partnerships are further propelling the market forward. With major players actively participating in mergers and acquisitions, the market is set for robust expansion in the coming years.

Request for A Sample Of The Global Parenteral Nutrition Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=6705&type=smp
May 23, 2024
5 Key Insights On The Generic Central Nervous System Drugs Market 2024
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Generic Central Nervous System Drugs Global Market Report 2024, the generic central nervous system drugs market is expected to show significant growth in the forecast period.

Market Overview
The generic central nervous system (CNS) drugs market has been expanding robustly. It is expected to grow from $83.71 billion in 2023 to $89.47 billion in 2024, at a compound annual growth rate (CAGR) of 6.9%. This growth has been driven by several factors:
- Increasing number of surgeries
- Strong growth in emerging markets
- Increased pharmaceutical R&D
- Aging population
- Rising healthcare expenditure
Future Market Projections
Looking ahead, the CNS drugs market is poised for continued strong growth, projected to reach $117.21 billion by 2028 at a CAGR of 7.0%. The key drivers for this growth include:
- Growing government initiatives for mental health awareness
- Rise in healthcare expenditure
- Increasing geriatric population
- Strong pipeline of drugs
View More On The Generic Central Nervous System Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report

Emerging Trends
Several major trends are expected to shape the CNS drugs market in the coming years:
- Investment in wearable technology
- Use of biomarkers in CNS drug development
- Modifying existing drugs for improved efficacy
- Investment in drug pipeline
- 3D printing for drug manufacturing
- Collaborations with research institutions and established companies
Rising Incidence of Mental Health Disorders
The increasing incidence of mental health disorders is a significant driver for the growth of the generic CNS drugs market. Mental health disorders, which impair cognition, emotional regulation, or conduct, require effective management. Generic CNS drugs offer affordable and accessible treatment options. For instance, in November 2022, the Health and Social Care Information Centre reported that the proportion of 17- to 19-year-olds in the UK with a suspected mental disorder grew from 17.4% in 2021 to 25.7% in 2022.

Key Companies in the Market
Several major companies are leading the way in the generic CNS drugs market:
- Biogen Inc.
- Johnson & Johnson
- Hoffmann-La Roche Ltd.
- Novartis AG
- UCB
- Sanofi
- Pfizer Inc.
- Merck KGaA
- Sumitomo Dainippon Pharma
- Amgen
- Abbott Laboratories
- Janssen Pharmaceutica
- Teva Canada
- Accord Healthcare Inc.
Innovative Solutions in the CNS Market
Product innovations are a key trend in the CNS market. Companies are focusing on developing innovative products to strengthen their market positions. For example, in December 2021, Intra-Cellular Therapies Inc. launched CAPLYTA, a treatment for depressive episodes associated with bipolar I or II disorder in adults. CAPLYTA is the only medication approved by the FDA for treating depressive disorders associated with both bipolar I and bipolar II, showing a positive profile in terms of weight, cardiometabolic parameters, and extrapyramidal symptoms.

Strategic Acquisitions
Strategic acquisitions are also driving growth in the CNS market. In November 2022, Avenue Therapeutics acquired Baergic Bio, enhancing Avenue’s capability to create medications addressing unmet medical needs in the CNS field.

Market Segmentation
The CNS drugs market is segmented into various categories:
1. By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2. By Drug Classification: Branded Drugs, Generic Drugs
3. By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4. By Route of Administration: Oral, Intravenous, Intranasal/Inhalation, Other Routes of Administration
5. By Mode of Purchase: Over-the-counter Drugs, Prescription-Based Drugs
6. By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Regional Insights
North America was the largest region in the generic CNS drugs market in 2023. The region’s robust healthcare infrastructure and high healthcare expenditure contribute to its market dominance.

Conclusion
The generic CNS drugs market is set for significant growth, driven by rising healthcare needs, technological advancements, and strategic industry moves. With continued innovation and increasing mental health awareness, the market is well-positioned to address the growing demand for effective CNS treatments.

Request A Sample Of The Global Generic Central Nervous System Drugs Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=9315&type=smp
May 23, 2024
What’s The Growth Forecast For Alpha Mannosidosis Market Through 2024-2033?
The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Introduction:
- Rapid expansion characterizes the alpha mannosidosis market, with staggering growth projected in recent and forthcoming years.
- From $12.77 billion in 2023 to an estimated $15.26 billion in 2024, the market is propelled by a compound annual growth rate (CAGR) of 19.5%.
- This blog delves into the market’s trajectory, highlighting key drivers, trends, and influential players shaping its landscape.
1. Driving Forces Behind Market Growth:
- Emerging markets and urbanization contribute to market expansion.
- Increased demand for man-made fibers boosts market demand.
- Government initiatives, particularly in the textile industry, bolster growth.
1. Projections and Influential Factors:
- Forecast predicts market escalation to $29.62 billion by 2028, driven by global population growth and urbanization.
- Factors such as e-commerce, sportswear demand, and organized retail penetration fuel this growth.
- Trends include the rise of enzyme therapy, hematopoietic stem cell transplantation, and cisterna magna infusion.
View More On The Alpha Mannosidosis Market Report 2024 – https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report
1. Regulatory Support Propelling Growth:
- Regulatory backing, particularly for rare disease drug approvals, serves as a significant growth catalyst.
- Initiatives like the FDA’s support for rare disease treatments prioritize advancements in this sector.
- Orphan drug designation offers incentives, including tax credits and market exclusivity, stimulating market growth.
1. Biopharmaceutical R&D Investments:
- Surge in biopharmaceutical R&D investments significantly contributes to market expansion.
- Increased understanding of alpha mannosidosis molecular basis drives innovation in potential treatments.
- Notable investments by companies like Merck and Roche fuel research and development initiatives.
1. Strategic Acquisitions:
- Chiesi Farmaceutici’s acquisition of Amryt Pharma for $1.25 billion strengthens its rare diseases portfolio.
- The acquisition adds Amryt Pharma’s approved commercial products to Chiesi’s offerings, enhancing its global presence.
1. Market Segmentation:
- Segmented by therapy type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), and Other Therapies.
- Indications include Type I, Type II, and Type III.
- End-users comprise hospitals and specialty clinics.
1. Regional Insights:
- North America led the market in 2023, while Asia-Pacific is poised for the fastest growth in the forecast period.
Conclusion:
- The alpha mannosidosis market’s exponential growth trajectory reflects a confluence of factors, from regulatory support to strategic investments.
- With innovations in therapy and increasing market penetration, the sector is poised for sustained expansion.
- Collaborative efforts across regulatory bodies, pharmaceutical companies, and research institutions are vital for realizing the market’s full potential.
Request A Sample Of The Global Alpha Mannosidosis Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=4093&type=smp
May 22, 2024